Gout Therapeutics Market

Biologics have witnessed rapid adoption and are replacing NSAIDS and corticosteroids owing to better results. Hence, the biologics segment is anticipated to expand rapidly and is likely to gain gout therapeutics, which drives the market growth in the forecast period.

The major factors driving the market's growth are the rising adoption of biologics and increasing R&D on regenerative medicines, technological advancements in imaging modalities improved. This condition can be treated or prevented using drugs such as nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and urate-lowering agents.

Increasing product approvals by regulatory authorities are expected to drive the growth of the gout disease treatment market. Manufacturers adopt acquisition & collaboration and new product development strategies to tap the unmet needs of a large proportion of the patient pool. For instance, in December 2018, SunGen Pharma, a privately held company, received the U.S. FDA approval for Prednisone (generic version of Deltasone), a drug with various strengths 10 mg, 20 mg, and 50 mg tablets, to treat various conditions such as arthritis, gout, blood disorders, immune system disorders, and others.

Demand for effective therapeutics for gout treatment is increasing. Numerous pipeline products and recent approvals of drugs to treat gout therapeutics are expected to a new opportunity for the market. New medications are being developed, such as halogenate, estimated to target renal transporters of uric acid, primarily URAT1 and OAT4, acting as uricosuric agents. Arhalofenate has been investigated for the treatment of Gout and Hyperuricemia. A Phase IIb study published in the April 7 issue of Nature Reviews Rheumatology demonstrated the dual mode of action of arhalofenate has a significant advantage over other urate-lowering therapies that can prompt an initial increase in flare-up risk.

Furthermore, new xanthine oxidase inhibitors, Topiloric and Uriadec, have been developed and labeled in Japan by Fujiyakuhin Co., Ltd. Japan and Sanwa Kagaku Kenkyusho Co., Ltd. Japan, respectively. Besides, URC102 was originated from both JW Pharmaceutical and Chugai Pharmaceutical (Roche). Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients. Physicians have rapidly prescribed urate-lowering drugs to control uric acid levels in patients suffering from gout. Hence, a rise in the number of promising drug pipelines and rapid acceptance of new drugs are expected to be a unique market opportunity.

The Covid – 19 pandemics are expected to impact the gout therapeutics market's growth over the forecast period. 

According to the CreakyJoints, in May 2020, people with gout may be considered in a higher-risk group for potential COVID-19 complications. The coronavirus (COVID 19) pandemic and lockdowns in various countries worldwide have impacted the financial status of businesses across all sectors. The private healthcare sector is one of the sectors, which has been majorly impacted by the COVID 19 pandemic.

With the ongoing COVID-19 pandemic, several companies are testing their drugs for their treatment. For instance, on June 22nd, 2020, antiviral drug Favipiravir (Fabiflu) was approved to treat mild to moderate COVID-19 patients will be commercialized full scale in a week, says drugmaker Glenmark Pharmaceuticals. The Drug Controller General of India approved the antiviral for 'restricted emergency use' to treat mild to moderate cases, which accounts for a majority of COVID-19 infections.

Colchicine, an anti-inflammatory drug used to treat gout and rheumatic disease, may be a promising treatment for COVID-19, a randomized, open-label trial suggests. In the Greek Study in the Effects of Colchicine in COVID-19 Complications Prevention (GRECCO-19), investigators randomly assigned 105 patients who had COVID-19 to receive either the standard of care or the standard of care plus colchicine for 3 weeks. They found that for patients in the colchicine group, the time to clinical deterioration improved, although there were no significant differences between the groups in cardiac and inflammatory biomarkers.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com